Location
Dover Library Large Conference Room
Start Date
21-3-2025 2:30 PM
End Date
21-3-2025 3:30 PM
Session Chair
Dr. Meredith Rowe
Mentor
Dr. Meredith Rowe
Description
Determining whether the drug Semaglutide, also known as Ozempic or Wegovy, is not only an effective treatment for weight loss, but also for management of type II diabetes and obesity-related heart failure, such as adverse cardiac remodeling and left atrial volume increase.
Included in
Session IA: Biology Presentation 3 - Beyond Weight Loss: The Effects of the GLP-1 Agonist, Semaglutide, on Weight Care, Type II Diabetes Management, and Cardiac Function in Obese Patients
Dover Library Large Conference Room
Determining whether the drug Semaglutide, also known as Ozempic or Wegovy, is not only an effective treatment for weight loss, but also for management of type II diabetes and obesity-related heart failure, such as adverse cardiac remodeling and left atrial volume increase.